R-Tech Ueno announces arbitration result against Takeda Pharma
While not accepting the claims of R-Tech Ueno, the arbitral award said the supply agreement among R-Tech Ueno, Takeda and Sucampo executed in 2004 regarding the exclusive supply
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.